2024 Nuclear Pharmacy
Conference (Sat. Only)
6 hrs. CPE

2024 Nuclear Pharmacy<br>Conference (Sat. Only)<br>6 hrs. CPE

2024 Nuclear Pharmacy
Conference (Sat. Only)
6 hrs. CPE

NUCLEAR PHARMACY CONFERENCE (Pharmacist)

Saturday, October 5, 2024 

Nuclear Medicine in Pediatrics                     8:00am-9:30am  

Elizabeth Rhoda, PharmD, RPh, Purdue University Nuclear Pharmacy Fellow

Upon completion of this activity, participants will be able to: Recognize commonly used pediatric nuclear medicine studies and protocols; Identify pearls and considerations for pediatric use of radiopharmaceuticals; Summarize key points regarding pediatric radiobiology; Evaluate different dosing methods for pediatrics and calculate correct doses for pediatrics; Explore advantages and challenges with using PET MRI vs PET CT pediatrics.

UAN: 0675-0000-24-031-L01-P

 

Cancer Associated Fibroblast (CAF) and Current Clinical Trial Diagnostic Agents

9:30am-11:00am

Garcia Simon Clark, PharmD, MS, ANP, CCP, BCNP, Kindred Healthcare, Pharmacy Supervisor

Upon completion of this activity, participants will be able to: Describe fibroblast activation protein and its role in cancer; Discuss multiple cancer type detection using fibroblast labeled with a radiotracer; Evaluate the clinical trials using fibroblast detection.

UAN: 0675-0000-24-032-L01-P

 

PET on the Mind: Radiopharmaceuticals for Brain Imaging

11:15am-12:45pm

Elizabeth Rayes, PharmD, Brigham and Women’s Hospital Nuclear Pharmacy, RadioPharmacist

Upon completion of this activity, participants will be able to: Describe Beta-Amyloid and its role in Alzheimer's; Discuss the use of F18 Beta-Amyloid imaging agents; Evaluate clinical trials on the use of tau & microglial radiotracers.

UAN: 0675-0000-24-033-L01-P

 

Germanium 68/Gallium 68 Generator Best Practices                                      

12:45pm-2:15pm

Jay Simon, RPh, ANP, Managing Director North America, Eckert & Zeigler

Upon completion of this activity, participants will be able to: Discuss the methods for production of Gallium 68 to be incorporated into a drug product; Describe the steps of eluting a GalliPharm generator and the process of measuring the Germanium 68 breakthrough; Explain best sterile techniques when eluting the gallium generator either in an ISO 8 or ISO 5 environment.

UAN: 0675-0000-24-034-L01-P

 

 

No Comments

Comments are closed.